MedPath

Assessment the effect of Carvedilol in preventing Heart failure in breast cancer patients.

Phase 3
Conditions
Breast Cancer.
Malignant neoplasm of breast
Registration Number
IRCT2017042433619N1
Lead Sponsor
Vice chancellor for research of Baqiyatallah University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
50
Inclusion Criteria

breast cancer patients under treatment with herceptin or antracyclines.
Exclusion criteria: EF less than50%; Significant Valvular Heart Disease; GFR<30ml/h/m2; Hepatic Failure; Contraindications for beta blockers; Symptoms of Heart Failure.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eft and Right Ventricule Function. Timepoint: 3 months after treatment. Method of measurement: Speckle Tracking Echocardiography.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath